Literature DB >> 26238094

Factors associated with the intensification of treatment in rheumatoid arthritis in clinical practice.

Antonio Naranjo1, Laura Cáceres2, José Ángel Hernández-Beriaín3, Félix Francisco2, Soledad Ojeda2, Sigrid Talaverano4, Javier Nóvoa-Medina3, José Adán Martín4, Esmeralda Delgado5, Elisa Trujillo5, Fátima Álvarez6, Laura Magdalena6, Carlos Rodríguez-Lozano2.   

Abstract

The aim of the present study was to analyse the patterns of treatment adjustment in rheumatoid arthritis (RA) patients with active disease in routine clinical care. This was a cross-sectional study of consecutive patients with RA conducted in five hospitals. Activity scales (DAS28-ESR) and function (HAQ) were measured, as well as whether ultrasound was performed as part of the assessment. Treatment decision (no changes/reduction/intensification) and time to the next scheduled visit were the outcomes variables. Associated factors were analysed by multilevel regression models. A total of 343 patients were included (77 % women, mean age 57 years, mean RA duration 10 years), of whom 44 % were in remission by DAS28. Treatment was continued in 202 (59 %) patients, reduced in 57 (16 %), and intensified in 83 (24 %). In the 117 patients with active RA (DAS28 ≥ 3.2), treatment was intensified in 61 (52 %). Factors associated with treatment intensification were physician and patient VAS, and DAS28, but not the centre. In the multilevel regression analysis with intensification of treatment as dependent variable, the following factors were significantly associated: DAS28 [OR 3.67 (95 % CI 2.43-5.52)], patient VAS [OR 1.04 (95 % CI 1.01-1.08)], and have performed an ultrasound [OR 3.36 (95 % CI 1.47-7.68)]. Factors associated with time to the next scheduled visit (an average of 4.3 months) were patient and physician VAS, DAS28, and centre. In clinical practice, half of the patients with active RA maintain or reduce the treatment. The decision to intensify treatment in active RA as recommended by a treat-to-target strategy is complex in practice.

Entities:  

Keywords:  DAS28; Rheumatoid arthritis; Treat to target; Ultrasonography

Mesh:

Substances:

Year:  2015        PMID: 26238094     DOI: 10.1007/s00296-015-3332-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  16 in total

1.  Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan.

Authors:  Yuko Kaneko; Takao Koike; Hiromi Oda; Kazuhiko Yamamoto; Nobuyuki Miyasaka; Masayoshi Harigai; Hisashi Yamanaka; Naoki Ishiguro; Yoshiya Tanaka; Tsutomu Takeuchi
Journal:  Mod Rheumatol       Date:  2014-06-20       Impact factor: 3.023

Review 2.  Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?

Authors:  Daniel H Solomon; Asaf Bitton; Jeffrey N Katz; Helga Radner; Erika M Brown; Liana Fraenkel
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

3.  Impact of the use of musculoskeletal ultrasound by rheumatologists in patients with shoulder and hand complaints compared with traditional clinical care.

Authors:  Antonio Naranjo; F Gabriel Jiménez-Núñez; Julio Medina-Luezas; J Miguel Senabre; Ana Rodríguez-García; Mónica Vázquez; Carlos Santos-Ramírez; María Alvarez de Buergo; María López-Lasanta; Estibaliz Loza
Journal:  Clin Exp Rheumatol       Date:  2012-10-17       Impact factor: 4.473

4.  Effect of rheumatologist education on systematic measurements and treatment decisions in rheumatoid arthritis: the metrix study.

Authors:  Janet Pope; Carter Thorne; Alfred Cividino; Kurt Lucas
Journal:  J Rheumatol       Date:  2012-10-15       Impact factor: 4.666

5.  Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study.

Authors:  Maxime Dougados; Henri Nataf; Ghislaine Steinberg; Stéphanie Rouanet; Bruno Falissard
Journal:  Rheumatology (Oxford)       Date:  2012-10-25       Impact factor: 7.580

Review 6.  After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?

Authors:  Richard J Wakefield; Maria Antonietta D'Agostino; Esperanza Naredo; Maya H Buch; Annamaria Iagnocco; Lene Terslev; Mikkel Ostergaard; Marina Backhaus; Walter Grassi; Maxime Dougados; Gerd R Burmester; Benazir Saleem; Eugenio de Miguel; Cristina Estrach; Kei Ikeda; Marwin Gutierrez; Robert Thompson; Peter Balint; Paul Emery
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

7.  Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH study.

Authors:  Lonnie Pyne; Vivian P Bykerk; Gilles Boire; Boulos Haraoui; Carol Hitchon; J Carter Thorne; Edward C Keystone; Janet E Pope
Journal:  J Rheumatol       Date:  2012-09-01       Impact factor: 4.666

8.  Treating rheumatoid arthritis to target: the patient version of the international recommendations.

Authors:  M P T de Wit; J S Smolen; L Gossec; D M F M van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-04-07       Impact factor: 19.103

9.  Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.

Authors:  Boulos Haraoui; Josef S Smolen; Daniel Aletaha; Ferdinand C Breedveld; Gerd Burmester; Catalin Codreanu; José Pereira Da Silva; Maarten de Wit; Maxime Dougados; Patrick Durez; Paul Emery; João Eurico Fonseca; Allan Gibofsky; Juan Gomez-Reino; Winfried Graninger; Vedat Hamuryudan; Maria José Jannaut Peña; Joachim Kalden; Tore K Kvien; Ieda Laurindo; Emilio Martin-Mola; Carlomaurizio Montecucco; Pedro Santos Moreno; Karel Pavelka; Gyula Poor; Mario H Cardiel; Ewa Stanislawska-Biernat; Tsutomu Takeuchi; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-07-29       Impact factor: 19.103

10.  Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy.

Authors:  James Dale; David Purves; Alex McConnachie; Iain McInnes; Duncan Porter
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-01       Impact factor: 4.794

View more
  2 in total

1.  Management of rheumatoid arthritis: what happens and what does not happen in real life.

Authors:  Daniel Aletaha
Journal:  Rheumatol Int       Date:  2015-12-19       Impact factor: 2.631

Review 2.  Real-world evidence in rheumatic diseases: relevance and lessons learnt.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2019-02-06       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.